1. Home
  2. RR vs CTNM Comparison

RR vs CTNM Comparison

Compare RR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Richtech Robotics Inc. Class B

RR

Richtech Robotics Inc. Class B

HOLD

Current Price

$1.92

Market Cap

483.0M

Sector

N/A

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$12.73

Market Cap

507.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RR
CTNM
Founded
2016
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
483.0M
507.0M
IPO Year
2023
2024

Fundamental Metrics

Financial Performance
Metric
RR
CTNM
Price
$1.92
$12.73
Analyst Decision
Hold
Buy
Analyst Count
2
4
Target Price
$4.00
$19.00
AVG Volume (30 Days)
6.7M
322.8K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
$5,045,000.00
N/A
Revenue This Year
$75.68
N/A
Revenue Next Year
$78.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.99
N/A
52 Week Low
$1.69
$3.35
52 Week High
$7.43
$16.33

Technical Indicators

Market Signals
Indicator
RR
CTNM
Relative Strength Index (RSI) 34.57 45.21
Support Level $1.81 $11.54
Resistance Level $2.04 $13.18
Average True Range (ATR) 0.14 0.99
MACD 0.02 0.07
Stochastic Oscillator 11.00 43.75

Price Performance

Historical Comparison
RR
CTNM

About RR Richtech Robotics Inc. Class B

Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: